Post-COVID-19 syndrome in outpatients: a cohort study

Florian Desgranges[1], Eliana Tadini[1], Aline Munting[1], Jean Regina[1], Paraskevas Filippidis[1], Benjamin Viala[1], Eleftherios Karachalias[2], Véronique Suttels[1], David Haefliger[1], Eleftheria Kampouri[1,3], Mathias Van Singer[1], Jonathan Tschopp[1], Laurence Rochat Stettler[1], Siméon Schaad[1], Thomas Brahier[1], Olivier Hugli[4], Yolanda Mueller Chabloz[5], Alexandre Gouveia[5], Onya Opota[6], Pierre-Nicolas Carron[4], Benoît Guery[1], Matthaios Papadimitriou-Olivgeris[1]*, Noémie Boillat-Blanco[1]*, the RegCOVID research group.

* Equal contribution to this work

Members of the RegCOVID group are listed in the acknowledgement section

[1]Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Switzerland; [2]Data Scientist, Cardiff, England; [3]Service of Hospital Preventive Medicine, Lausanne University Hospital and University of Lausanne, Switzerland; [4]Emergency Department, University Hospital of Lausanne and Lausanne University, Switzerland; [5]Department of Family Medicine, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland; [6]Institute of Microbiology, Lausanne University and University Hospital of Lausanne, Switzerland

Word count:

- Abstract: 263
- Manuscript: 2986

ABSTRACT

Background

Some patients experience long-term symptoms after COVID-19, but data on outpatients with mild-to-moderate COVID-19 are scarce.

Objective

To describe persisting symptoms more than 3 months after infection in PCR-confirmed COVID-19 in comparison to negative SARS-CoV-2 PCR outpatients and to identify predictors of long-term symptoms in COVID-19.

Setting

Outpatient clinics of a Swiss university center.

Patients

418 symptomatic outpatients with PCR-confirmed COVID-19 (COVID-positive) and 89 negative SARS-CoV-2 PCR (COVID-negative).

Design

Prospective cohort study.

Measurements

Predefined long-term symptoms were evaluated though a phone interview >3 to 10 months after diagnosis.

Associations between long-term symptoms and PCR test result, as well predictors of persisting symptoms in COVID-positive were evaluated by multivariate logistic regression including potential confounders (age, sex, smoking, comorbidities, time of the phone survey).

Results

The study population consisted mostly of young (median of 41 versus 36 years in COVID-positive and COVID-negative, respectively; p=0.020) health care workers (67% versus 82%;

p=0.006).. Persisting symptoms were reported by 223 (53%) COVID-positive and 33 (37%) COVID-negative (*p*=0.006). Overall, 21% COVID-positive and 15% COVID-negative (p=0.182) consulted a doctor for these symptoms. Four surveyed symptoms were independently associated with COVID-19: fatigue (adjusted odds ratio [aOR] 2.14, 95%CI 1.04-4.41), smell/taste disorder (26.5, 3.46-202), dyspnea (2.81, 1.10-7.16) and memory impairment (5.71, 1.53-21.3). Among COVID-positive, female gender (aOR 1.67, 95% CI 1.09-2.56) and overweight/obesity (1.67, 1.10-2.56) were predictors of persisting symptoms.

Limitations

Undiagnosed SARS-CoV-2 infection in COVID-negative cannot be completely excluded.

Conclusion

More than half of COVID-positive outpatients report persisting symptoms up to 10 months after infection and 21% seek medical care for this reason. These data suggest that post-COVID syndrome places a significant burden on society and especially healthcare systems.

INTRODUCTION

More than one year after the first cases of Coronavirus disease 2019 (COVID-19) (1), the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic remains a constant threat challenging the capacity of healthcare systems and affecting well-being of many individuals. The clinical presentation and outcome of acute COVID-19 is well described, most patients presenting with mild disease and only a minority needing hospital admission (2). While most affected people experience complete resolution of their symptoms after two to six weeks (3,4), symptoms lasting more than 3 months have been reported in social media (5–7) and in observational studies (8–13). Three studies reported that a large number of patients have persisting symptoms for more than 6 months after COVID-19: one study including adults discharged from hospital (14) and two studies including outpatients with mild-to-moderate disease (15,16). Recent guidelines defined post-COVID-19 syndrome as the persistence of signs and symptoms for more than 3 months after infection in the absence of an alternative diagnosis (17).

Although they represent the vast majority of cases, data on long-term consequences in outpatients with mild-to-moderate COVID-19 are still scarce. To the best of our knowledge, no study compared the prevalence of persisting symptoms among patients screened for similar symptoms, between those tested positive for SARS-CoV-2 and those tested negative. Therefore, the association between PCR-confirmed COVID-19 and long-term symptoms is not well established. Furthermore, no study explored the factors associated with persisting symptoms in outpatients. These data are crucial as they may modify patients' follow-up after their infection and influence public health vaccination strategies by identifying additional population groups that should be prioritized.

We aimed to compare the prevalence of symptoms persisting for more than 3 months between SARS-CoV-2 PCR-confirmed (COVID-positive) and PCR-negative (COVID-negative) patients in outpatient clinics, and to identify predictors of persisting symptoms in COVID-positive.

METHODS

Study design, setting and participants

This cohort study recruited consecutive PCR-confirmed COVID-19 patients (COVID-positive group) during their initial visit in the emergency department (ED) or in the SARS-CoV-2 screening center of the University hospital of Lausanne, as well as in the two outpatient clinics of the University of Lausanne, Switzerland, between February 26th and April 27th 2020. During the study period, SARS-CoV-2 screening was restricted to symptomatic patients (i.e. symptoms of acute respiratory tract infection, anamnestic fever or sudden loss of smell or taste) with at least one risk factor for severe COVID-19 (i.e. ≥ 65 years old or presence of a comorbidity such as hypertension, diabetes, cancer, chronic cardiac or respiratory disease, immunosuppression) and to symptomatic health workers (18). Validated nucleic acid amplification tests were used and a dedicated trained medical team performed the nasopharyngeal swabs (19).

We included a control group of outpatients attending the same health facilities during the same period with symptoms suggestive of COVID-19 (cough and/or dyspnea) at presentation, but a negative PCR SARS-CoV-2 result in nasopharyngeal swab (COVID-negative group). This group was part of a prospective cohort of patients with acute respiratory infections previously described (20,21).

47 We excluded patients who 1) did not have a documented health assessment at the time of
48 the test, 2) were hospitalized (for more than 24 hours) on the day of initial visit or within the
49 following 30 days, 3) were unable to understand the phone survey due to a language barrier
50 or a cognitive impairment, 4) declined to participate, 5) were not reachable for the phone
51 interview after at least two attempts or 6) had the phone survey less than 3 months after the
52 initial visit. Patients who had a positive SARS-CoV-2 test performed in another location before
53 the initial visit in the study centers were excluded, as we also planned to evaluate the impact
54 of the infection on healthcare system (i.e. medical consultations for persisting symptoms).
55 Moreover, we excluded COVID-negative patients who declared having a documented (PCR or
56 serology) SARS-CoV-2 infection after the initial consultation up to the phone follow-up.

57 **Procedures**

58 We retrospectively extracted data from the patients' electronic medical records:
59 demographics, medical history, initial clinical presentation, and SARS-CoV-2 real-time reverse
60 transcriptase PCR (RT-PCR) cycle thresholds. We prospectively conducted a structured and
61 standardized phone survey more than 3 three months after SARS-CoV-2 diagnosis to collect
62 information on (1) persisting symptoms at the time of the call, (2) secondary hospital
63 admission within 30 days of the initial consultation, (3) medical consultation for persisting
64 symptoms until the call, and (4) anthropometric data. The survey included 14 pre-defined
65 symptoms: fatigue, muscle weakness, dyspnea, cough, thoracic pain, smell or taste disorder,
66 blurred vision, headache, memory impairment, loss of balance, numbness, nausea, sleep
67 disorder, and hair loss. Dyspnea was further categorized according to New York Heart
68 Association (NYHA) grades (22). The calls were performed by physicians of the infectious
69 diseases service of the University Hospital of Lausanne.

70 All data were entered in the Lausanne University Hospital's electronic database "regCOVID"
71 using the REDCap® platform (Research Electronic Data Capture v8.5.24, Vanderbilt University,
72 Tennessee, USA) (20,23).

73 **Definitions**

74 Long-term symptoms were defined as symptoms that appeared during the acute infection
75 phase, were still present at time of the phone call (i.e. >3 months after the initial consultation)
76 and were not explained by an alternative diagnosis. Smell or taste disorder included partial or
77 complete loss of that sense. Numbness included hypoesthesia and paresthesia.

78 To account for the timing of symptoms assessment, we classified COVID-positive patients in
79 three equivalent periods according to the time between SARS-CoV-2 diagnosis (initial
80 consultation) and the phone interview: first period: >3 months to 5 months after diagnosis,
81 second period: >5 months to 7 months after diagnosis, and third period: >7 months to 10
82 months after diagnosis.

83 **Statistical analyses**

84 Demographics, clinical features at the time of initial consultation, consultation for persisting
85 symptoms and prevalence of long-term symptoms (any symptom or individualized symptoms)
86 were compared between COVID-positive and COVID-negative by Mann Whitney-U, *chi-*
87 squared, or Fisher tests as appropriate, as well as between COVID-positive patients surveyed
88 during the three different periods after SARS-CoV-2 diagnosis by 1-way ANOVA, Kruskal-Wallis
89 or chi-squared as appropriate. A p value <0.05 was considered statistically significant. The
90 association between COVID-19 and long-term symptoms was evaluated by multivariate
91 logistic regression including potential confounders (age, sex, smoking, comorbidities, period
92 of the phone survey). The independent association between the previously mentioned factors

and long-term symptoms in COVID-positive was evaluated by multivariate logistic regression including the same potential confounders.

STATA (version 15.1, Stata Corp, College Station, TX, USA) statistical software and GraphPad Prism 8.3 (GraphPad, San Diego, CA, USA) were used for analyses.

Ethics

The project was approved by the Ethics Committee of the Canton of Vaud, Switzerland. All participants gave their verbal consent to participate in this study during the phone interview (project-ID CER-VD 2020-01107 and 2019-02283).

RESULTS

A total of 956 symptomatic patients had a RT-PCR-confirmed COVID-19 between February 26th and April 27th, 2020. We excluded 198 patients who were admitted within 30 days of the initial visit (151 on the day of the first visit and 47 in the following 30 days) and 340 with other exclusion criteria described in Figure 1. The remaining 418 (44%) COVID-positive patients were included in the analysis. We contacted 131 COVID-negative patients who consulted with symptoms suggestive of COVID-19 and had a negative SARS-CoV-2 RT-PCR between March 31st and April 26th, 2020. We excluded 19 patients who had a positive SARS-CoV-2 test (RT-PCR or serology) between the time of the initial visit and the time of the phone survey, 17 who could not be reached, 3 who refused to participate, 2 who did not speak one of the investigators' languages and one who died. The remaining 89 (68%) COVID-negative patients were included in the analysis.

Demographics and clinical presentation

In both groups, there was a majority of women and health care workers. Approximately a third of patients suffered from a comorbidity, mainly obesity, arterial hypertension, and asthma

117 (Table 1). Most patients were tested within the first week of symptom onset and had normal
118 vital signs at initial consultation. Compared to COVID-negative, COVID-positive were slightly
119 older and less often health care workers, active smokers, and asthmatic. COVID-positive
120 reported less often a history of fever, dyspnea, or sore throat at the time of evaluation.
121 The study team assessed long-term symptoms via the phone survey at a median of 105 days
122 (interquartile range [IQR], 121-204 days) and 242 days (IQR 236-248 days) after the initial
123 consultation in the COVID-positive and COVID-negative groups, respectively (p<0.001). The
124 study team called 190 (45%) COVID-positive during the first period (>3 to 5 months after the
125 initial visit), 102 (24%) during the second period (>5 to 7 months) and 126 (30%) during the
126 third period (>7 to 10 months). Patients surveyed in the first period were significantly older,
127 less often health-care workers and had more comorbidities than those in the two other
128 periods (Appendix Table 1). The study team called all COVID-negative during the third period.
129 ***Long-term symptoms***
130 At the time of the phone survey, 223/418 (53%) COVID-positive and 33/89 (37%) COVID-
131 negative patients (p=0.006) reported the presence of any long-term symptom (Figure 1A,
132 Table 2).
133 In COVID-positive, the main reported symptoms were fatigue (n=132, 32%), smell or taste
134 disorder (n=93, 22%), dyspnea (n=66, 16%), headache (n=50, 12%), memory impairment
135 (n=48, 11%), hair loss (n=43, 10%), and sleep disorder (n=41, 10%). The prevalence of long-
136 term symptoms was similar during the 3 periods surveyed (Figure 2B). In COVID-negative, the
137 main reported symptoms were fatigue (n=15, 17%), headache (n=10, 11%), sleep disorder
138 (n=10, 11%), and dyspnea (n=7, 8%).
139 COVID-positive reported more often smell or taste disorder (p=0.001), fatigue (p=0.006) and
140 memory impairment (p=0.003) than COVID-negative. The prevalence of other symptoms was

141 similar between COVID-positive and COVID-negative. The proportions of patients with ≥ 2 and
142 ≥ 3 symptoms were greater in COVID-positive than COVID-negative (38% *vs* 19%; *p*=0.001 and
143 23% *vs* 9.0 %; *p*=0.002, respectively). The proportion of patients requiring a medical
144 consultation for persisting symptoms was similar between COVID-positive and COVID-
145 negative (21% versus 15%, p=0.182).

146 ***Independent association between COVID-positive status and long-term symptoms***

147 After adjusting for potential confounders, COVID-positive status was a predictor for reporting
148 any symptom (adjusted odds ratio [aOR] 2.04, 95% CI 1.14-3.67; *p*=0.02), fatigue (aOR 2.14,
149 95% CI 1.04-4.41; *p*=0.04), dyspnea (aOR 2.81, 95% CI 1.10-7.16; *p*=0.03), smell or taste
150 disorder (aOR 26.5, 95% CI 3.46-202; p<0.01) and memory impairment (aOR 5.71, 95% CI 1.53-
151 21.3; p=0.01) at the time of the phone survey (Table 2). Of note, dyspnea associated with
152 limited physical activity (NYHA ≥2), as well as other long-term symptoms were not associated
153 with COVID status.

154 ***Predictors of long-term symptoms in COVID-positive***

155 While 57% of women presented long-term symptoms, only 47% of men did (p=0.049). While
156 59% of overweight/obese patients presented long-term symptoms, only 49% of patients with
157 healthy weight did (p=0.041). After adjusting for potential confounders, independent
158 predictors of reporting any long-term symptoms were still female gender (aOR 1.67, 95% CI
159 1.09-2.56; p=0.019) and overweight/obesity (aOR 1.67, 95% CI 1.10-2.56; p=0.017; Table 3).
160 The same predictors were associated with long-term fatigue. Predictor of dyspnea was
161 overweight/obesity. Predictor of smell or taste disorder was female gender. Predictor of
162 memory impairment was active smoking (Figure 3). Predictors of other long-term symptoms,
163 which were not associated with COVID status, are presented in Appendix table 2.

164

DISCUSSION

In a large cohort of PCR-confirmed COVID-19 outpatients, we evaluated the prevalence of persisting symptoms 3 to 10 months after diagnosis and compared it with a cohort of negative SARS-CoV-2 PCR patients included during the same period with a similar clinical presentation. In these study populations consisting mostly of young and healthy participants, most working as health care workers, we showed that 53% of patients with PCR-confirmed COVID-19 report persisting symptoms, while 37% with negative SARS-CoV-2 PCR do. Interestingly, only 4 out of the 14 surveyed persisting symptoms were independently associated with COVID status, i.e. fatigue, smell or taste disorder, dyspnea and memory impairment.

The type and prevalence of long-lasting symptoms in COVID-positive are consistent with existing literature. In a systematic review and meta-analysis of studies evaluating the prevalence of persisting symptoms up to 110 days after COVID-19 of various severities, the five more common symptoms were fatigue (58%), headache (44%), attention disorder (27%), hair loss (25%) and dyspnea (24%), while agueusia, anosmia and memory loss were reported by 23%, 21% and 16% of the studies populations (24). Two studies evaluating hundreds of laboratory-confirmed COVID-19 outpatients have reported the prevalence of symptoms lasting more than 6 months after diagnosis: 33-39% participants with at least one symptom, 14-55% with fatigue, 22% with dyspnea, and 14% with loss of sense of smell or taste (15,16). The differences between studies may be explained by various patients' selection criteria, data collection methods, and definitions of symptoms.

Strikingly, the proportion of COVID-positive patients with long-term symptoms was similar between the three surveyed periods. Our findings are supported by a few longitudinal studies, which analyzed the evolution of residual symptoms and showed a stable proportion after the acute phase and up to 7 months (7,25).

189 In our study 23% of COVID-positive required at least one additional medical visit for COVID-
190 19-related symptoms, which is close to the proportion of 36% found in another study (16).
191 These data show the burden on ambulatory health-care facilities related to post-COVID-19
192 syndrome. However, we did not find a statistical difference in the proportion of patients
193 requiring an additional medical consultation between COVID-positive and COVID-negative,
194 which might be due to a lack of statistical power.
195 Our results shed more light on the association between SARS-CoV-2 infection and long-term
196 symptoms. While some symptoms were more frequent in PCR-confirmed COVID-19
197 outpatients, the prevalence of others was not different to SARS-CoV-2 PCR negative patients.
198 In particular, the prevalence of headache and sleep disorder, two predominant persisting
199 symptoms in COVID-negative patients, was similar between COVID-negative and COVID-
200 positive. Both symptoms may originate from mixed etiologies including psychosocial factors
201 and/or non-specific post-infectious consequences. The COVID-19 pandemic has greatly
202 impacted our psychosocial behaviors due to confinement, social distancing, mask wearing and
203 changing work conditions. Some symptoms may be a consequence of these unprecedented
204 changes (26). Furthermore, long-term sequelae after an acute respiratory infection may not
205 be limited to coronaviruses, as shown with severe H7N9 infection leading to lung disability
206 and psychological impairment at 2 years of follow-up (27).
207 Another study evaluating 6-month sequelae in outpatients with COVID-19 included a small
208 control group of healthy volunteers and showed that 33% of COVID-positive outpatients and
209 5% of volunteers presented symptoms (15). However, the limited sample size (21 healthy
210 volunteers) and their normal health status prevents comparison with our results. Another
211 report also showed that 26% of seropositive health care workers present long-term symptoms
212 8 months after mild COVID, while only 9% of seronegative do (28). Inclusion of patients

213 irrespective of the presence of symptoms (no or mild prior symptoms) might explain the lower
214 prevalence compared to our results.
215 Overweight/obesity was an independent predictor of the presence of any long-term
216 symptom, fatigue and dyspnea. Overweight and obesity are increasingly associated with poor
217 outcomes in COVID-19. In a systematic review and meta-analysis of 22 studies and in a large
218 CDC analysis in the United States population, overweight and/or obesity in COVID-19 were
219 associated with an increased risk of hospital admission, invasive ventilation, and death,
220 especially among patients younger than 60 years-old (29,30). Another study reported an
221 association between body mass index and persisting symptoms after more than 28 days (31).
222 The mechanisms responsible for post-COVID-19 syndrome are not understood yet and may
223 be multiple (32,33). Long-term symptoms may be due to higher initial organ damages related
224 to dysregulated inflammatory response. This may be true in people with overweight and
225 obesity (34–36), since the adipose tissue has a high expression of angiotensin-converting
226 enzyme 2 receptors and secretes pro-inflammatory cytokines.
227 While previous studies showed that male gender is a risk factor for severe outcome in COVID-
228 19 (37), we identified female gender as a predictor for post-COVID-19 syndrome and
229 specifically for persisting fatigue and smell or taste disorder. Although not always consistent,
230 some studies have described an association between female gender and long-COVID (31),
231 persisting fatigue (12–14), post-exertional polypnea (13), decreased rates of recovery (16),
232 and anxiety or depression (14,16). Gender differences in immunity, as illustrated by the higher
233 representation of women in autoimmune diseases (38), may explain divergent findings with
234 COVID-19.
235 Our study has some limitations. First, most surveyed symptoms are subjective and prone to
236 observer bias. Symptoms may also come from an intercurrent condition at the time of COVID-

237 19 diagnosis and not always represent sequelae of SARS-CoV-2 infection. However, inclusion
238 of a symptomatic control group supports the association between some symptoms and SARS-
239 CoV-2 infection. Furthermore, this reflects the clinical reality that physicians face in a post-
240 COVID consultation. Since the prevalence of most symptoms was lower than 10%, the absence
241 of difference may be due to a lack of statistical power to detect an association with COVID-19.
242 Our study suffers from a selection bias due to SARS-CoV-2 test criteria (health care workers or
243 presence of a risk factor of adverse outcome) at the time of the study, which may prevent
244 generalization of our findings to the broad population. In addition, we included a SARS-CoV-2
245 PCR negative control group, who had a slightly different clinical presentation (only patients
246 with acute respiratory symptoms) compared to COVID-positive (any symptom suggestive of
247 COVID-19). Furthermore, we cannot formally exclude that some COVID-negative had an
248 undiagnosed SARS-CoV-2 infection due to a false negative PCR result. However, we used a
249 validated SARS-CoV-2 RT-PCR test on a nasopharyngeal swab performed by a dedicated
250 trained medical team to minimize technical and sample collection bias (19,39).
251 In conclusion, our study shows that more than half of outpatients with mild-to-moderate
252 COVID-19 report long-term symptoms 3 to 10 months after diagnosis and that 21% seek
253 medical care for this reason. These data suggest that post-COVID syndrome places a significant
254 burden on society and especially healthcare systems. There is an urgent need to inform
255 physicians and political authorities about the natural long-term course of COVID-19 in order
256 to plan an appropriate and dedicated management of those with disabling persisting
257 symptoms.

DECLARATIONS

Acknowledgements

We thank all the patients who accepted to participate and make this study possible. We thank all healthcare workers of the triage center and of the emergency department of the University Hospital of Lausanne, who supported the study and managed COVID-19 suspected patients. We thank Nadia Cattaneo and Martin Delaloye who participated to patients' follow-up. We thank Tanguy Espejo and Luca Bosso who included patients in the COVID-negative group.

Members of the RegCOVID group (by alphabetical order): Pierre-Yves Bochud (Committee President), Florian Desgranges, Paraskevas Filippidis, David Haefliger, Eleftheria Evdokia Kampouri, Oriol Manuel (Committee Member), Aline Munting, Jean-Luc Pagani (Committee Member), Matthaios Papadimitriou-Olivgeris (Registry Coordinator and Committee Member), Jean Regina, Laurence Rochat Stettler, Véronique Suttels, Eliana Tadini, Jonathan Tschopp, Mathias Van Singer, Benjamin Viala, Peter Vollenweider (Committee member).

Authors' contributions

FD, MPO, NBB: study conception, study design, study performance, study management, patients' follow-up, data analysis, data interpretation and manuscript writing.

ET, AM: patients follow-up, data interpretation and manuscript writing.

JR, PF, BV, NS, DH, EK, MVS, JT, LRS: patients follow-up, data interpretation and critical review of the manuscript.

BG: study design, data interpretation and critical review of the manuscript.

OH, YMC, AG, PNC, BG: data interpretation and critical review of the manuscript.

EK: data analysis, interpretation, and critical review of the manuscript.

TB, SS: patients' inclusion, and critical review of the manuscript.

OO: microbiological data interpretation and critical review of the manuscript

MPO had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Funding

This work was supported by an academic award of the Leenaards Foundation (to NBB), the Infectious Disease Service and the emergency department of Lausanne University Hospital. The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript

BIBLIOGRAPHY

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727–33.

2. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239–42.

3. Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC, et al. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020. MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993–8.

4. Wang X, Xu H, Jiang H, Wang L, Lu C, Wei X, et al. Clinical features and outcomes of discharged coronavirus disease 2019 patients: a prospective cohort study. QJM: An International Journal of Medicine. 2020 Sep 1;113(9):657–65.

5. Banda JM, Singh GV, Alser OH, Prieto-Alhambra D. Long-term patient-reported symptoms of COVID-19: an analysis of social media data [Internet]. Infectious Diseases (except HIV/AIDS); 2020 Aug [cited 2021 Apr 7]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.07.29.20164418

6. Goërtz YMJ, Van Herck M, Delbressine JM, Vaes AW, Meys R, Machado FVC, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Research. 2020 Oct;6(4):00542–2020.

7. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact [Internet]. Infectious Diseases (except HIV/AIDS); 2020 Dec [cited 2021 Jan 19]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.12.24.20248802

8. Carfì A, Bernabei R, Landi F, Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020 Aug 11;324(6):603–5.

9. Carvalho-Schneider C, Laurent E, Lemaignen A, Beaufils E, Bourbao-Tournois C, Laribi S, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clinical Microbiology and Infection. 2021 Feb;27(2):258–63.

10. Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty-Day Outcomes Among Patients Hospitalized With COVID-19. Annals of Internal Medicine [Internet]. 2020 Nov 11 [cited 2021 Feb 12]; Available from: https://www.acpjournals.org/doi/10.7326/M20-5661

11. Garrigues E, Janvier P, Kherabi Y, Le Bot A, Hamon A, Gouze H, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. Journal of Infection. 2020 Dec;81(6):e4–6.

12. Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. Madeddu G, editor. PLoS ONE. 2020 Nov 9;15(11):e0240784.

13. Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clinical Microbiology and Infection. 2021 Jan 1;27(1):89–95.

14. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021 Jan 16;397(10270):220–32.

15. Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, et al. Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA Netw Open. 2021 Feb 19;4(2):e210830.

16. Menges D, Ballouz T, Anagnostopoulos A, Aschmann HE, Domenghino A, Fehr JS, et al. Estimating the burden of post-COVID-19 syndrome in a population-based cohort study of SARS-CoV-2 infected individuals: Implications for healthcare service planning [Internet]. Epidemiology; 2021 Mar [cited 2021 Mar 7]. Available from: http://medrxiv.org/lookup/doi/10.1101/2021.02.27.21252572

17. National Institute for Health and Care Excellence (NICE), the Scottish Intercollegiate Guidelines Network, (SIGN) and the Royal College of General Practitioners (RCGP). COVID-19 rapid guideline: managing the long-term effects of COVID-19. 2020 Dec 18;35.

18. Office fédéral de la santé publique OFSP. Nouveau Coronavirus (COVID-19) Critères de suspicion, de prélèvement d'échantillons et de déclaration [Internet]. 2020 [cited 2020 Apr 30]. Available from: https://www.bag.admin.ch/bag/fr/home/krankheiten/infektionskrankheiten-bekaempfen/meldesysteme-infektionskrankheiten/meldepflichtige-ik/meldeformulare.html

19. Opota O, Brouillet R, Greub G, Jaton K. Comparison of SARS-CoV-2 RT-PCR on a high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples. Pathog Dis. 2020 Nov 11;78(8).

20. Brahier T, Meuwly J-Y, Pantet O, Brochu Vez M-J, Gerhard Donnet H, Hartley M-A, et al. Lung ultrasonography for risk stratification in patients with COVID-19: a prospective observational cohort study. Clinical Infectious Diseases. 2020 Sep 17;ciaa1408.

21. Schaad S, Brahier T, Hartley M-A, Cordonnier J-B, Bosso L, Espejo T, et al. Point-of-care lung ultrasonography for early identification of mild COVID-19: a prospective cohort of outpatients in a Swiss screening center. medRxiv. 2021 Mar 26;2021.03.23.21254150.

22. The Criteria Committee of the New York Heart Association . Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. In: 9th ed. Boston, Mass: ed Little, Brown & Co; 1994. p. 253–256.

23. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019 Jul;95:103208.

24. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. medRxiv. 2021 Jan 30;2021.01.27.21250617.

25. Nguyen NN, Hoang VT, Lagier J-C, Raoult D, Gautret P. Long-term persistence of olfactory and gustatory disorders in COVID-19 patients. Clinical Microbiology and Infection. 2021 Jan;S1198743X20307813.

26. Alzueta E, Perrin P, Baker FC, Caffarra S, Ramos-Usuga D, Yuksel D, et al. How the COVID-19 pandemic has changed our lives: A study of psychological correlates across 59 countries. Journal of Clinical Psychology. 2021;77(3):556–70.

27. Chen J, Wu J, Hao S, Yang M, Lu X, Chen X, et al. Long term outcomes in survivors of epidemic Influenza A (H7N9) virus infection. Scientific Reports. 2017 Dec 8;7(1):17275.

28. Havervall S, Rosell A, Phillipson M, Mangsbo SM, Nilsson P, Hober S, et al. Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers. JAMA [Internet]. 2021 Apr 7 [cited 2021 Apr 18]; Available from: https://jamanetwork.com/journals/jama/fullarticle/2778528

29. Chu Y, Yang J, Shi J, Zhang P, Wang X. Obesity is associated with increased severity of disease in COVID-19 pneumonia: a systematic review and meta-analysis. European Journal of Medical Research. 2020 Dec 2;25(1):64.

30. Kompaniyets L, Goodman AB, Belay B, Freedman DS, Sucosky MS, Lange SJ, et al. Body Mass Index and Risk for COVID-19–Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death — United States, March–December 2020. MMWR Morb Mortal Wkly Rep. 2021 Mar 12;70(10):355–61.

31. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nature Medicine. 2021 Mar 10;1–6.

32. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020/07/12. 2020 Jul;26(7):1017–32.

33. Wang F, Kream RM, Stefano GB. Long-Term Respiratory and Neurological Sequelae of COVID-19. Med Sci Monit. 2020 Nov 1;26:e928996-1-e928996-10.

34. Albashir AAD. The potential impacts of obesity on COVID-19. Clin Med (Lond). 2020 Jul;20(4):e109–13.

35. Dicker D, Bettini S, Farpour-Lambert N, Frühbeck G, Golan R, Goossens G, et al. Obesity and COVID-19: The Two Sides of the Coin. OFA. 2020;13(4):430–8.

36. Stefan N, Birkenfeld AL, Schulze MB. Global pandemics interconnected — obesity, impaired metabolic health and COVID-19. Nature Reviews Endocrinology. 2021 Jan 21;1–15.

37. Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun. 2020 Dec;11(1):6317.

38. Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. Front Neuroendocrinol. 2014 Aug;35(3):347–69.

39. Mueller L, Scherz V, Greub G, Jaton K, Opota O. Computer-aided medical microbiology monitoring tool: a strategy to adapt to the SARS-CoV-2 epidemic and that highlights RT-PCR consistency [Internet]. Infectious Diseases (except HIV/AIDS); 2020 Jul [cited 2021 Apr 5]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.07.27.20162123

TABLES

Table 1: Characteristics of patients according to SARS-CoV-2 RT-PCR result (COVID-negative and COVID-positive).

Characteristics	COVID-negative (N=89)	COVID-positive (N=418)	*P value*
Demographics			
Age in years	36 (29-47)	41 (31-54)	0.020
Female gender	57 (64%)	261 (62%)	0.776
Active smoking	27 (30%)	46 (11%)	<0.001
Health care worker	73 (82%)	281 (67%)	0.006
BMI (kg/m^2)	24 (22-27)	24 (22-28)	0.412
Comorbidities			
Any comorbidity	32 (36%)	130 (31%)	0.372
Arterial Hypertension	8 (9.0%)	65 (16%)	0.109
Diabetes Mellitus	1 (1.1%)	22 (5.3%)	0.098
Cardiovascular Disease	5 (5.6%)	10 (2.4%)	0.157
Asthma	16 (18%)	43 (10%)	0.040
Malignancy (hematological/solid organ)	0 (0.0%)	15 (3.6%)	0.085
Chronic inflammatory disease	1 (1.1%)	13 (3.1%)	0.482
Overweight [a] or obesity	36 (40%)	189 (45%)	0.411
Obesity	11 (12%)	72 (17%)	0.260
Other comorbidities[b]	4 (4.5%)	12 (2.9%)	0.500
Symptoms at initial consultation			
Days from symptoms onset	2.0 (2.0-4.0)	3.0 (2.0-7.0)	0.088
Fever	52 (58%)	172 (41%)	0.003
Sore throat	35 (39%)	79 (19%)	<0.001
Rhinorrhoea	43 (48%)	205 (49%)	0.901
Smell or taste disorder	9 (10%)	73 (17%)	0.087
Cough	68 (76%)	305 (73%)	0.504
Dyspnea	49 (55%)	67 (16%)	<0.001
Myalgia/arthralgia	53 (60%)	249 (60%)	0.997
Diarrhea	19 (21%)	60 (14%)	0.099
Signs at initial consultation			
Temperature (°C)	36.9 (36.6-37.3)	37.2 (36.7-37.9)	<0.001
Heart rate (beats/min)	90 (78-98)	86 (75-98)	0.168
Respiratory rate (breath/min)	18 (16-20)	17 (15-20)	0.419
SpO_2 on ambient air (%)	97 (97-98)	97 (96-98)	0.405
Microbiological information			
SARS-CoV-2 cycle threshold value	-	22 (18-27)	-
Outcome			
Consultation for persisting symptoms	13 (15%)	87 (21%)	0.182

Data are number (%) of patients or median (interquartile range).
[a]"Any comorbidity" does not included overweight; [b]Other comorbidities: 7 Neurological Disease, 5 Chronic Kidney Disease, 4 Chronic Obstructive Pulmonary Disease, 4 Cirrhosis.

Missing data: 1 BMI, 98 days from symptoms onset, 39 temperature, 84 heart rate, 310 respiratory rate, 41 SpO2 on ambient air, 7 SARS-CoV-2 cycle threshold value.
Two-sided chi-squared or Fisher tests were performed when comparing proportions, and Mann–Whitney U tests were performed for continuous variables.
BMI: body mass index; SpO2: oxygen saturation; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; RT-PCR: real time reverse transcriptase polymerase chain reaction.

Table 2. Association between long-term symptoms (any and individualized symptoms) assessed at the time of phone survey and COVID positive status.

	COVID-negative	COVID-positive	Bivariate analysis *		Multivariable analysis * °	
Long-term symptoms	**(n=89)**	**(n=418)**	**OR (95% CI)**	P value	**aOR (95% CI)**	P value
Any symptoms	33 (37%)	223 (53%)	1.94 (1.21-3.11)	0.006	2.04 (1.14-3.67)	0.017
Fatigue	15 (17%)	132 (32%)	2.28 (1.26-4.12)	0.006	2.14 (1.04-4.41)	0.039
Muscle weakness	2 (2.2%)	8 (1.9%)	0.85 (0.18-4.07)	0.837	0.65 (0.08-5.21)	0.688
Dyspnea	7 (7.9%)	66 (16%)	2.20 (0.97-4.96)	0.059	2.81 (1.10-7.16)	0.030
Dyspnea NYHA≥2	4 (4.5%)	30 (7.2%)	1.64 (0.56-4.79)	0.363	1.11 (0.29-4.32)	0.881
Cough	3 (3.4%)	25 (6.0%)	1.82 (0.54-6.2)	0.334	1.16 (0.24-5.56)	0.849
Thoracic pain	4 (4.5%)	21 (5.0%)	1.12 (0.38-3.36)	0.834	1.11 (0.27-4.54)	0.886
Smell or taste disorder	1 (1.1%)	93 (22%)	25.2 (3.46-183)	0.001	26.5 (3.46-202)	0.002
Blurred vision	2 (2.2%)	20 (4.8%)	2.19 (0.50-9.53)	0.298	3.17 (0.63-16.0)	0.163
Headache	10 (11%)	50 (12%)	1.07 (0.52 -2.21)	0.847	1.27 (0.52-3.09)	0.601
Loss of balance	3 (3.4%)	12 (2.9%)	0.85 (0.23-3.07)	0.801	0.37 (0.05-2.62)	0.322
Memory impairment	3 (3.4%)	48 (11%)	3.72 (1.13-12.2)	0.003	5.71 (1.53-21.3)	0.010
Numbness	1 (1.1%)	14 (3.4%)	3.05 (0.40-23.5)	0.284	1.71 (0.14-20.3)	0.670
Nausea	3 (3.4%)	11 (2.6%)	0.77 (0.21-2.84)	0.700	1.30 (0.24-7.08)	0.760
Sleep disorder	10 (11%)	41 (9.8%)	0.86 (0.41-1.79)	0.685	1.03 (0.42-2.52)	0.950
Hair loss	5 (5.6%)	43 (10%)	1.92 (0.74-5.01)	0.179	1.18 (0.36-3.93)	0.783

Data are number (%) of patients. *symptoms associated with COVID-positive status. ° analysis adjusted for age, sex, smoking, overweight/obesity, diabetes, asthma, hypertension, cancer, cardiovascular disease, chronic inflammatory disease, period of the phone survey.
OR: odds ratio; aOR: adjusted odds ratio; CI: confidence interval; NYHA: New York Heart Association.

Table 3. Factors associated with the presence of any long-term symptom during the phone survey in COVID-positive patients.

	No symptom	Any symptom	Bivariate analysis *		Multivariable analysis * °	
Characteristics	**(n=195)**	**(n=223)**	**OR (95% CI)**	P value	**aOR (95% CI)**	P value
Demographics						
Age in years	41 (30-54)	42 (33-54)	1.01 (0.95-1.08)	0.702	1.02 (0.94 to 1.10)	0.682
Female gender	112 (57%)	149 (67%)	1.49 (1.00-2.22)	0.049	1.67 (1.09 to 2.56)	0.019
Active smoking	16 (8.2%)	30 (13%)	1.74 (0.92-3.30)	0.090	1.72 (0.89 to 3.34)	0.107
Comorbidities						
Overweight or obesity	78 (40%)	112 (50%)	1.50 (1.02-2.21)	0.041	1.67 (1.10 to 2.56)	0.017
Diabetes Mellitus	12 (6.2%)	10 (4.5%)	0.72 (0.30-1.70)	0.447	0.69 (0.28 to 1.72)	0.426
Asthma	19 (9.7%)	24 (11%)	1.12 (0.59-2.11)	0.732	1.11 (0.58 to 2.14)	0.749
Hypertension	30 (15%)	35 (16%)	1.02 (0.60-1.74)	0.930	0.96 (0.51 to 1.81)	0.912
Malignancy	5 (2.6%)	10 (4.5%)	1.78 (0.60-5.31)	0.298	1.63 (0.50 to 5.30)	0.414
Cardiovascular Disease	5 (2.6%)	5 (2.2%)	0.87 (0.25-3.06)	0.830	1.05 (0.27 to 4.09)	0.948
Chronic inflammatory Disease	5 (2.6%)	8 (3.6%)	1.41 (0.45-4.40)	0.549	1.18 (0.35 to 3.94)	0.790
Timing of phone survey						
>3 to 5 months	87 (45%)	103 (46%)	1.07 (0.72-1.57)	0.747	1.06 (0.65 to 1.73)	0.808
>5 to 7 months	47 (24%)	55 (25%)	1.03 (0.66-1.61)	0.894	1.05 (0.61 to 1.80)	0.856
>7 to 10 months	61 (31%)	65 (29%)	0.90 (0.59-1.37)	0.635	1.00 (reference)	

Data are number (%) of patients or median (interquartile range). *symptoms associated with the presence of any long-term symptom. ° analysis adjusted for age, sex, smoking, overweight/obesity, diabetes, asthma, hypertension, cancer, cardiovascular disease, chronic inflammatory disease, period of the phone survey.
Missing data: 1 BMI
Odds ratio for age indicates the risk of the presence of any symptom per 5-year age increase.
OR: odds ratio; aOR: adjusted odds ratio; CI: confidence interval.

FIGURE LEGENDS

Figure 1: Study flow-chart

Figure 2: Proportions of patients with long-term symptoms at the time of the phone survey.

A) Comparison between COVID-positive (positive SARS-CoV-2 RT-PCR) and COVID-negative (negative SARS-CoV-2 RT-PCR); **B)** Comparison between COVID-positive surveyed during three different period: Period 1: >3 to 5 months after SARS-CoV-2 diagnosis; Period 2: >5 to 7 months after SARS-CoV-2 diagnosis; Period 3: >7 to 10 months after SARS-CoV-2 diagnosis. Data are shown as proportions (%) with 95% confidence intervals.

Figure 3: Factors associated with the presence of selected long-term symptoms (fatigue, smell or taste disorder, dyspnea and memory impairment) during the phone survey in COVID-positive patients.

Selected symptoms are those associated with COVID status.

Multivariable analysis adjusted for age, sex, smoking, overweight/obesity, diabetes, asthma, hypertension, cancer, cardiovascular disease, chronic inflammatory disease, period of the phone survey. Adjusted odds ratio for age indicates the risk of fatigue, smell/taste disorder, dyspnea or memory impairment per 5-year age increase.

aOR: adjusted odds ratio; CI: confidence interval.

*p<0.05


956 patients with a positive RT-PCR SARS-CoV-2 result screened for inclusion
538 had at least one exclusion criteria:
- 198 were hospitalized within 30 days of their first visit
- 174 were unreachable
- 99 were included in another study
- 39 declined to participate
- 10 did not speak investigators' languages
- 8 had an incomplete CRF
- 4 died before the call
- 3 were beyond study period limits
- 2 were unable to consent
- 1 had no documented health assessment at the date of test
418 COVID-positive included in the analysis


A
COVID-negative
COVID-positive
Proportion of patients with 95% CI
80
60
40
20
0
Any symptom
Fatigue
Muscle weakness
Dyspnea
Cough
Thoracic pain
Smell or taste disorder
Blurred vision
Headache
Memory impairment
Loss of balance
Numbness
Nausea
Sleep disorder
Hair loss


B
>3 to 5 months
>5 to 7 months
>7 to 10 months
Proportion of COVID-positive patients with 95% CI
80
60
40
20
0
Any symptom
Fatigue
Muscle weakness
Dyspnea
Cough
Thoracic pain
Smell or taste disorder
Blurred vision
Headache
Memory impairment
Loss of balance
Numbness
Nausea
Sleep disorder
Hair loss


Fatigue
aOR (95% CI)
Age
1.08 (0.99 to 1.17)
Women
1.61 (1.00 to 2.59) *
Current smoker
1.79 (0.92 to 3.46)
Overweigth/Obesity
1.70 (1.08 to 2.67) *
Diabetes
0.76 (0.27 to 2.13)
Asthma
0.95 (0.46 to 1.95)
Hypertension
1.00 (0.51 to 1.93)
Malignancy
0.80 (0.25 to 2.57)
Cardiovascular Disease
0.21 (0.03 to 1.81)
Chronic Inflammatory Disease
3.40 (1.00 to 11.6)
Timing of phone survey
>3 to 5 months
1.23 (0.73 to 2.10)
>5 to 7 months
1.27 (0.71 to 2.29)
>7 to 10 months
1.00 (ref)
0
5
10
15


Smell/Taste disorder
aOR (95% CI)
0.98 (0.88 to 1.07)
1.88 (1.09 to 3.22) *
1.82 (0.92 to 3.62)
1.01 (0.61 to 1.67)
1.14 (0.39 to 3.38)
1.17 (0.55 to 2.46)
1.31 (0.61 to 2.78)
0.92 (0.23 to 3.66)
1.13 (0.21 to 6.11)
0.74 (0.15 to 3.65)
1.05 (0.58 to 1.90)
1.44 (0.77 to 2.69)
1.00 (ref)
0
2
4
6


Dyspnea
aOR (95%)
Age
0.93 (0.83 to 1.05)
Women
1.71 (0.93 to 3.16)
Current smoker
1.15 (0.51 to 2.61)
Overweigth/Obesity
2.02 (1.14 to 3.59) *
Diabetes
0.23 (0.03 to 1.84)
Asthma
1.05 (0.43 to 2.53)
Hypertension
1.19 (0.51 to 2.82)
Malignancy
0.33 (0.04 to 2.88)
Cardiovascular Disease
2.57 (0.45 to 14.6)
Chronic Inflammatory Disease
2.07 (0.50 to 8.63)
Timing of phone survey
>3 to 5 months
0.83 (0.43 to 1.60)
>5 to 7 months
0.90 (0.44 to 1.85)
>7 to 10 months
1.00 (ref)
0
5
10
15


Memory impairment
aOR (95%)
0.98 (0.85 to 1.12)
1.10 (0.56 to 2.17)
3.51 (1.63 to 7.58) *
1.79 (0.93 to 3.44)
0.76 (0.16 to 3.67)
1.24 (0.47 to 3.29)
0.93 (0.33 to 2.64)
2.96 (0.64 to 13.6)
1.02 (0.11 to 9.83)
1.00 (1.00 to 1.00)
0.73 (0.33 to 1.62)
1.27 (0.57 to 2.80)
1.00 (ref)
0
5
10
15